Enzymatically Modified Isoquercitrin: Production, Metabolism, Bioavailability, Toxicity, Pharmacology, and Related Molecular Mechanisms.

Int J Mol Sci · 2022 · PMC9738368 · PMID 36499113

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

In both cases, during 8-week treatments with EMIQ (100 mg/day), a clear trend was noticed toward reducing ocular symptoms such as itching, lacrimation, and congestion.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.